9 October 2019 - Deborah Wilkes
The US dietary supplement industry wants rapid action on cannabidiol (CBD) products, Probi has revised its 2019 sales forecast and Thornton & Ross is expanding its capacity.
US industry wants action on CBD
Four trade associations representing the US dietary supplement industry have joined forces to urge Congress to “ensure consumer safety and provide legal clarity” in the cannabidiol (CBD) marketplace.
In a letter, they call on Congress “to pass legislation to clarify that CBD derived from the hemp plant is a lawful dietary ingredient if the dietary supplement containing the CBD meets established product safety and quality criteria”.
The letter states that the lengthy time the Food and Drug Administration (FDA) has projected for completion of a rulemaking in the face of the rapidly-growing CBD marketplace should compel Congress to take quick action now on several fronts.
In addition, the letter urges Congress to provide the FDA with "statutory authority and substantial additional resources to set a clear regulatory framework for the marketplace and to better assure consumer protection".
The four associations are the American Herbal Products Association (AHPA), the Consumer Healthcare Products Association (CHPA), the Council for Responsible Nutrition (CRN), and the United Natural Products Alliance (UNPA).
Probi revises sales forecast
Swedish probiotics specialist Probi has revised its sales forecast for 2019 following “weaker market growth” in the US.
The company said sales in the first nine months of 2019 were expected to be SEK460 million (USD47.5 million), representing a rise of 4% as reported compared to the same period a year earlier. Excluding the impact of currency translations, sales would be unchanged.
Probi said its “goal of growing organically faster than the global market is unlikely to be met in 2019”. The company added that sales for the full year were expected to be in line with the previous year.
Thornton & Ross expands capacity
Thornton & Ross aims to have a new 600 square metres bottling and filling line in action at its plant in Huddersfield, UK, by 1 January 2020.
The company said the “seven-figure state-of-the-art facility” was the “most significant investment” made at its site by parent company Stada Arzneimittel.
Forty permanent jobs will be created.